Evosep Joins P4ML to Power World’s Largest Multi-Omic Human Health Study of Two Million Samples

Evosep, a global leader in robust, high-throughput proteomics technologies, has been selected as the proteomics platform provider for the P4ML - OMICAssist Study—the world's largest multi-omic precision medicine initiative, launched by P4ML alongside its strategic academic, health regulatory, and semi-state partners in the United Arab Emirates.

Evosep headquarters in Odense, Denmark. Image Credit: Evosep

Over the next five years, the study will screen more than two million individuals, integrating gut microbiome, metabolomics, lipidomics, proteomics, exposomics, and wearable biosensor data to deliver real-time, personalized insights and reshape the future of healthcare.

As part of this groundbreaking effort, Evosep will supply its cutting-edge LC-MS-based proteomics technology to enable high-throughput, reproducible protein analysis at scale. To support this initiative, Evosep Biolabs will provide expert guidance in setting up the proteomics workflows, ensuring they are fully automated, consistent, and scalable at P4ML lab. This infrastructure will be critical to deliver the robust, high-quality data required for systems biology approaches and AI-driven health modeling.

"Evosep's mission is to make proteomics-based medicine accessible," said Morten Bern, CEO at Evosep. "We are honored to contribute our technology and expertise to a project that not only redefines personalized medicine but also sets a new global benchmark for multi-omic research."

The United Arab Emirates doesn't just imagine the future—it builds it. As a Future100 company, P4ML is proud to lead the world's largest MultiOMIC health study. Mass spectrometry plays a pivotal role in unlocking the biological signals that drive health and disease. With Evosep and our global network of partners, we are establishing the infrastructure and insights needed to usher in a new era of predictive, preventive, and personalized medicine."

Patrick J. Moloney, Founder and CEO, P4ML

The P4ML OMICAssist Study is a cornerstone of the future health innovation strategy and is closely aligned with national initiatives. With rigorous data governance and strong translational focus, the study is poised to set new global standards for precision public health.

The OMIC-Assist initiative is part of the Dubai Fitness Challenge and reflects the UAE's commitment to global healthcare innovation. With secure, ethical data governance and a focus on real-world impact, the study is poised to reshape how health is understood, monitored, and managed.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evosep. (2025, June 18). Evosep Joins P4ML to Power World’s Largest Multi-Omic Human Health Study of Two Million Samples. AZoLifeSciences. Retrieved on June 20, 2025 from https://www.azolifesciences.com/news/20250617/Evosep-Joins-P4ML-to-Power-Worlde28099s-Largest-Multi-Omic-Human-Health-Study-of-Two-Million-Samples.aspx.

  • MLA

    Evosep. "Evosep Joins P4ML to Power World’s Largest Multi-Omic Human Health Study of Two Million Samples". AZoLifeSciences. 20 June 2025. <https://www.azolifesciences.com/news/20250617/Evosep-Joins-P4ML-to-Power-Worlde28099s-Largest-Multi-Omic-Human-Health-Study-of-Two-Million-Samples.aspx>.

  • Chicago

    Evosep. "Evosep Joins P4ML to Power World’s Largest Multi-Omic Human Health Study of Two Million Samples". AZoLifeSciences. https://www.azolifesciences.com/news/20250617/Evosep-Joins-P4ML-to-Power-Worlde28099s-Largest-Multi-Omic-Human-Health-Study-of-Two-Million-Samples.aspx. (accessed June 20, 2025).

  • Harvard

    Evosep. 2025. Evosep Joins P4ML to Power World’s Largest Multi-Omic Human Health Study of Two Million Samples. AZoLifeSciences, viewed 20 June 2025, https://www.azolifesciences.com/news/20250617/Evosep-Joins-P4ML-to-Power-Worlde28099s-Largest-Multi-Omic-Human-Health-Study-of-Two-Million-Samples.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.